Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place?

Annals of Clinical Biochemistry

Volumn 50, Issue 5, 2013, Pages 473-478

  van Egmond, Remco ^a   Barclay, Murray L ^a   Chin, Paul K L ^a   Sies, Christiaan W ^b   Florkowski, Christopher M ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Analytes; Clinical studies; Enzymes; Laboratory methods; Purine metabolism; Quality assurance and control; TPMT

Indexed keywords

DIMETHYL SULFOXIDE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ANALYTICAL PARAMETERS; ARTICLE; BIOLOGICAL VARIATION; DIAGNOSTIC PROCEDURE; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PHENOTYPE; PRIORITY JOURNAL; PROBABILITY; PURINE METABOLISM; QUALITY CONTROL; VARIANCE;

EID: 84890205188     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563212473441     Document Type: Article

References (18)

1. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417.
2. Lennard L, Van Loon JA and Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-154.
3. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-146.
4. Dervieux T, Medard Y, Baudouin V, et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol 1999; 48: 793-800.
5. McLeod HL, Relling MV, Liu Q, Pui CH and Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85: 1897-1902.
6. Giverhaug T, Klemetsdal B, Lysaa R and Aarbakke J. Intraindividual variability in red blood cell thiopurine methyltransferase activity. Eur J Clin Pharmacol 1996; 50: 217-220.
7. Weinshilboum RM, Raymond FA and Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 323-333.
8. Sies C, Florkowski C, George P, et al. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. NZ Med J 2005; 118: U1324.
9. Fraser CG. Biological Variation: From Principles to Practice. Washington, DC: AACC Press, 2001.
10. Daperno M, Sostegni R, Canaparo R, et al. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30: 843-853.
11. Szumlanski CL and Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
12. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102: 2747-2753.
13. Dilger K, Schaeffeler E, Lukas M, et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 2007; 29: 1-5.
14. Gardiner SJ, Gearry RB, Begg EJ, Zhang M and Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ threefold. Clin Gastroenterol Hepatol 2008; 6: 654-660; quiz 604.
15. Sanderson J, Ansari A, Marinaki T and Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004; 41: 294-302.
16. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915.
17. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6- mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713.
18. Ford L, Prout C, Gaffney D and Berg J. Whose TPMT activity is it anyway? Ann Clin Biochem 2004; 41: 498-500.